Q-omics provides the consensus-scored DIO2 profile across patient tissues and cancer cell-line models. DIO2 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, DIO2 is differentially expressed in 15, with the highest sampling consensus in THCA. Additionally, DIO2 RNA expression shows 14,892 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight UCEC, THCA, and BRCA as cancer lineages where DIO2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DIO2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DIO2 survival associations across molecular data types. DIO2 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DIO2 RNA expression–survival associations across cancer types. High DIO2 expression shows unfavorable associations in ACC, SCLC and KIRP, but favorable associations in UCEC, COAD and BRCA. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for DIO2 RNA expression.
This table summarizes DIO2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for DIO2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DIO2 shows lower tumor expression in THCA and HNSC and higher tumor expression in LUAD, COAD, STAD and LUSC. The THCA box plot shows higher DIO2 RNA expression in normal versus tumor tissue (log2 FC = −3.440, t-test p < 0.001).
This table shows molecular features associated with DIO2 in patient tissues and cancer cell lines. In patient samples, DIO2 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, DIO2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and LUNG_NSCLC_LUAD.
